Early enlarging cavitation after percutaneous radiofrequency ablation of lung tumors: Incidence, risk factors and outcome

A major complication of microwave ablation in a patient with surgically treated ground-glass opacity

ABSTRACT

A 64-year-old male patient with pulmonary ground-glass opacity (GGO) underwent microwave ablation treatment. An early cavity occurred and induced subsequent serious major complications of pneumothorax and hemothorax. The chest tube intervention was conducted, but the symptoms deteriorated. Finally, pulmonary wedge resection was conducted, and a lung tissue tear of 5 cm was observed during the operation.

Perioperative real-life experiences and care needs of patients undergoing lung cancer ablation: A qualitative study

BackgroundLung cancer (LC) remains the most common malignancy in China with high mortality. The early stages of LC tend to manifest no apparent symptoms or only mild coughing, to which patients attach no importance.Objective: To gain an in-depth understanding of the perioperative real experiences and care needs of patients undergoing lung cancer ablation, to make a reliable basis for the construction of care programs for perioperative complications of lung cancer ablation, and to further improve the quality of perioperative clinical care interventions for such patients.MethodsSixteen lung cancer patients undergoing lung cancer ablation who were hospitalized in the Department of Oncology of our hospital from April 2023 to October 2023 as well as six healthcare professionals of Shanghai Pulmonary Hospital were recruited by purposive sampling. Semi-structured interviews were conducted with the enrolled individuals by using a phenomenological approach, and the Colaizzi's 7-step analysis method was used to analyze, summarize and refine the themes of the interview data.ResultsA total of seven study themes were identified emotional reactions of ablation patients, financial stress, needs for information on treatment outcomes and health education during recovery, reassurance of living and care needs during hospitalization, concerns about the treatment of complications, correct and detailed preoperative assessment, and doctor-nurse collaboration for good management of patient complications.ConclusionIn the clinical nursing of patients with lung cancer, we should construct standardized perioperative ablation nursing process as soon as possible, create diversified health guidance materials, strengthen the continuity of nursing after discharge, improve patients' understanding of the disease, pay attention to their emotional changes, and provide more maintenance support, so as to reduce complications and improve the quality of life of patients with lung cancer ablation.

Safety and efficacy of a novel transbronchial radiofrequency ablation system for lung tumours: One year follow-up from the first multi-centre large-scale clinical trial (BRONC-RFII)

BACKGROUND AND OBJECTIVE

Radiofrequency ablation (RFA) is an emerging treatment of lung cancer, yet it is accompanied by certain safety concerns and operational limitations. This first multi-centre, large-scale clinical trial aimed to investigate the technical performance, efficacy and safety of an innovative transbronchial RFA system for lung tumours.

METHODS

The study enrolled patients with malignant lung tumours who underwent transbronchial RFA using an automatic saline microperfusion system between January 2021 and December 2021 across 16 medical centres. The primary endpoint was the complete ablation rate. The performance and safety of the technique, along with the 1-year survival rates, were evaluated.

RESULTS

This study included 126 patients (age range: 23-85 years) with 130 lung tumours (mean size: 18.77 × 14.15 mm) who had undergone 153 transbronchial RFA sessions, with a technique success rate of 99.35% and an average ablation zone size of 32.47 mm. At the 12-month follow-up, the complete ablation rate and intrapulmonary progression-free survival rates were 90.48% and 88.89%, respectively. The results of patients with ground-glass nodules (GGNs) were superior to those of the patients with solid nodules (12-month complete ablation rates: solid vs. pure GGN vs. mixed GGN: 82.14% vs. 100% vs. 96.08%, p = 0.007). No device defects were reported. Complications such as pneumothorax, haemoptysis, pleural effusion, pulmonary infection and pleural pain were observed in 3.97%, 6.35%, 8.73%, 11.11% and 10.32% of patients, respectively. Two subjects died during the follow-up period.

CONCLUSION

Transbronchial RFA utilizing an automatic saline microperfusion system is a viable, safe and efficacious approach for the treatment for lung tumours, particularly for patients with GGNs.

Hydrodissection technique for pain relief during peri-microwave ablation in patients with subpleural non-small cell lung cancers

PURPOSE

This study aimed to assess the application value of the hydrodissection technique (HT) for pain relief during peri-microwave ablation (MWA) in patients with subpleural non-small cell lung cancers (NSCLCs).

METHODS

This retrospective study comprised 218 patients with subpleural NSCLCs who underwent computed tomography (CT)-guided percutaneous MWA. The patients were divided into two groups: HT-assisted MWA (HT group) and local pleural anesthesia (LPA)-assisted MWA (LPA group). Differences in the effective rates of pain relief during MWA, visual analog scale (VAS) scores post-MWA, complications, and complete ablative rates were assessed.

RESULTS

The HT group comprised 101 patients (62 males and 39 females; mean age, 61.93 ± 10.57 years), while the LPA group comprised 117 patients (66 males and 51 females; mean age, 62.95 ± 11.16 years). The effective rate of pain relief in the HT group (82/101 patients, 81.19%) was significantly higher than that in the LPA group (66/117 patients, 56.41%), (p < 0.0001). The VAS scores at 6, 12, 24, and 48 h post-MWA were not statistically different between the two groups. The incidence of pneumothorax (grade ≥3) was significantly lower in the HT group (11/101 patients, 10.89%) than in the LPA group (27/117, 23.07%), (p = 0.0161). The complete ablative rates at 1, 3, 6, 12, and 24 months post-MWA were comparable of two groups.

CONCLUSIONS

These results indicate that HT-assisted MWA of patients with subpleural NSCLCs could effectively provide pain relief and decrease the occurrence of pneumothorax, yielding a satisfactory local therapeutic response.

Pulmonary delivery of nano-particles for lung cancer diagnosis and therapy: Recent advances and future prospects

Although our understanding of lung cancer has significantly improved in the past decade, it is still a disease with a high incidence and mortality rate. The key reason is that the efficacy of the therapeutic drugs is limited, mainly due to insufficient doses of drugs delivered to the lungs. To achieve precise lung cancer diagnosis and treatment, nano-particles (NPs) pulmonary delivery techniques have attracted much attention and facilitate the exploration of the potential of those in inhalable NPs targeting tumor lesions. Since the therapeutic research focusing on pulmonary delivery NPs has rapidly developed and evolved substantially, this review will mainly discuss the current developments of pulmonary delivery NPs for precision lung cancer diagnosis and therapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies Diagnostic Tools > In Vivo Nanodiagnostics and Imaging.

Early enlarging cavitation after percutaneous microwave ablation of primary lung cancer

PURPOSE

This retrospective study assessed the incidence rate, risk factors, and clinical course of early enlarging cavitation after percutaneous microwave ablation (MWA) of primary lung cancer (PLC).

METHODS

This study included 557 lesions of 514 patients with PLC who underwent CT-guided percutaneous MWA between 1 January 2018 and 31 December 2021. Of these patients, 29 developed early enlarging cavitation and were enrolled in the cavity group, and 173 were randomly enrolled in the control group. Early enlarging cavitation of the lung was defined as the development of a cavity ≥30 mm within 7 days after MWA.

RESULTS

Overall, 31 (5.57%, 31/557 tumors) early enlarging cavitations occurred at an average of 5.83 ± 1.55 d after MWA. The risk factors were lesion contact with a large vessel (diameter ≥3 mm), lesion contact with the bronchus (diameter ≥2 mm), and a large ablated parenchymal volume. The cavity group had a higher incidence rate of delayed hydropneumothorax (12.9%) and bronchopleural fistula (9.68%) than the control group, resulting in a longer hospitalization (9.09 ± 5.26 days). Until Dec 31, 2022, 27 cavities disappeared after a mean of 217.88 ± 78.57 d (range, 111-510 d), two persisted, and two were lost to follow-up.

CONCLUSIONS

Early enlarging cavitation occurred in 5.57% PLC cases that underwent MWA, causing serve complications and longer hospitalization. The risk factors were ablated lesion contact with large vessels and bronchi, as well as a larger ablated parenchymal volume.

Irreversible electroporation and electrochemotherapy in oncology: State of the art

Thermal tumor ablation techniques including radiofrequency, microwave, LASER, high-intensity focused ultrasound and cryoablation are routinely used to treated liver, kidney, bone, or lung tumors. However, all these techniques are thermal and can therefore be affected by heat sink effect, which can lead to incomplete ablation, and thermal injuries of non-targeted tissues are possible. Under certain conditions, high voltage pulsed electric field can induce formation of pores in the cell membrane. This phenomenon, called electropermeabilization, is also known as "electroporation". Under certain conditions, electroporation can be irreversible, leading to cell death. Irreversible electroporation has demonstrated efficacy for the treatment of liver and prostate cancers, whereas data are scarce regarding pancreatic and renal cancers. During reversible electroporation, transient cell permeability can be used to introduce cytotoxic drugs into tumor cells (commonly bleomycin or cisplatin). Reversible electroporation used in conjunction with cytotoxic drugs shows promise in terms of oncological response, particularly for solid cutaneous and subcutaneous tumors such as melanoma. Irreversible and reversible electroporation are both not thermal ablation techniques and therefore open a new promising horizon for tumor ablation.

Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure

BACKGROUND

This retrospective study aimed to assess the safety and efficacy of microwave ablation for lung tumors adjacent to the interlobar fissures.

METHODS

From May 2020 to April 2021, 59 patients with 66 lung tumors (mean diameter, 16.9 ± 7.7 mm; range, 6-30 mm) adjacent to the interlobar fissures who underwent microwave ablation at our institution were identified and included in this study. Based on the relationship between the tumor and the interlobar fissure, tumors can be categorized into close to the fissure, causing the fissure, and involving the fissure. The complete ablation rate, local progression-free survival, complications, and associated factors were analyzed.

RESULTS

All 66 histologically proven tumors were treated using computed tomography-guided microwave ablation. The complete ablation rate was 95.5%. Local progression-free survival at 3, 6, 9, and 12 months were 89.4%, 83.3%, 74.2%, and 63.6%, respectively. The complications included pneumothorax (34.8%), pleural effusion (24.2%), cavity (18.2%), and pulmonary infection (7.6%). There were statistical differences in the incidence of pneumothorax, cavity, and delayed complications between the groups with and without antenna punctures through the fissure.

CONCLUSIONS

Microwave ablation is a safe and effective treatment for lung tumor adjacent to the interlobar fissure. Antenna puncturing though the interlobar fissure may be a potential risk factor for pneumothorax, cavity, and delayed complications.